HLB bioStepLtd Valuation

Is A278650 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A278650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A278650's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A278650's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A278650?

Key metric: As A278650 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A278650. This is calculated by dividing A278650's market cap by their current revenue.
What is A278650's PS Ratio?
PS Ratio	3.7x
Sales	₩49.17b
Market Cap	₩181.86b

A278650 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.7x
Enterprise Value/EBITDA	-54.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A278650's PS Ratio compare to its peers?

The above table shows the PS ratio for A278650 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16.3x
A038290 Macrogen	1.2x	16.9%	₩160.4b
A268600 Cellivery Therapeutics	10.9x	n/a	₩244.9b
A445680 Curiox Biosystems	49.4x	n/a	₩281.7b
A039860 NanoEntek	3.6x	n/a	₩105.0b
A278650 HLB bioStepLtd	3.7x	n/a	₩181.9b

Price-To-Sales vs Peers: A278650 is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (18.1x).

Price to Sales Ratio vs Industry

How does A278650's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
A245620 Eone Diagnomics Genome Center	0.8x	n/a	US$41.47m
A215380 WOOJUNG BIO	0.6x	n/a	US$20.05m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A278650 is good value based on its Price-To-Sales Ratio (3.7x) compared to the KR Life Sciences industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is A278650's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A278650 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A278650's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

-0.7%

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

2.1%

-41.2%